Effects of genistein on blood pressure: A systematic review and meta-analysis.

Autor: Hemati N; Internal Medicine Department, Kermanshah University of Medical Sciences, Kermanshah, Iran., Asis M; Internal Medicine Department, Isfahan University of Medical Sciences, Isfahan, Iran., Moradi S; Halal Research Center of IRI, FDA, Tehran, Iran; Nutritional Sciences Department, School of Nutritional Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran., Mollica A; Department of Pharmacy, G. d'Annunzio University of Chieti-Pescara, 66100 Chieti, Italy., Stefanucci A; Department of Pharmacy, G. d'Annunzio University of Chieti-Pescara, 66100 Chieti, Italy., Nikfar S; Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, and Evidence-Based Evaluation of Cost-Effectiveness and Clinical Outcomes Group, Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS) Tehran University of Medical Sciences, Tehran, Iran., Mohammadi E; R.R College of Pharmacy, Bangalore, India., Farzaei MH; Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Electronic address: mh.farzaei@gmail.com., Abdollahi M; Toxicology and Diseases Group (TDG), Pharmaceutical Sciences Research Center (PSRC), The Institute of Pharmaceutical Sciences (TIPS), and Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Mohammad@TUMS.Ac.Ir.
Jazyk: angličtina
Zdroj: Food research international (Ottawa, Ont.) [Food Res Int] 2020 Feb; Vol. 128, pp. 108764. Date of Electronic Publication: 2019 Oct 31.
DOI: 10.1016/j.foodres.2019.108764
Abstrakt: Genistein (4',5,7-trihydroxyisoflavone) is a phytoestrogen with potential health benefits in the prevention of cardiovascular disease. However, the evidence regarding its effects on hypertension has not been conclusive. Therefore, we examined the impact of oral genistein supplementation on systolic blood pressure (SBP) and diastolic blood pressure (DBP) via a systematic review and meta-analysis of randomized controlled trials (RCTs). PubMed, ISI Web of Science, Scopus and the Cochrane library databases (until August 2019) were searched to identify potential RCTs with information on genistein supplementation and hypertension. Weighted Mean Difference (WMD) was pooled using a random-effects model. Pooling four RCTs (four treatment arms) together did not show any significant reduction of SBP (WMD: -5.32 mmHg, 95% CI: -14.59 to 3.96) and DBP (WMD: -2.06 mmHg, 95% CI: -6.41 to 2.28) compared to that of the placebo group. However, subgroup analysis by intervention duration suggested that more than 6 months genistein supplementation in metabolic syndrome patients can significantly decrease SBP (WMD: -13.73 mmHg, 95% CI: -18.10 to -9.37) and DBP (WMD: -5.18 mmHg, 95% CI: -6.62 to -3.74). Generally, present study indicated that genistein supplementation had no effect on hypertension, but it seems that longer intervention duration of more than 6 months especially among metabolic syndrome patients may lead to the effectiveness of genistein.
(Copyright © 2019 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: